ReviewCell death & disease2025
The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The role of lysosome-dependent cell death in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.Medical oncology (Northwood, London, England) · 2026Article
- Immune Regulation and the Role of Extracellular Vesicles in Non-Small Cell Lung Cancer: Biological Mechanisms and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Smart Nanomaterials and Natural Biologics for Innate-Adaptive Immune Reprogramming: A Nanobiotechnology Framework for Translational Medicine.Nanomaterials (Basel, Switzerland) · 2026Review
- Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.Signal transduction and targeted therapy · 2026Article
- From Berry to Bedside: Translational Potential of Berry-Derived Phytochemicals in HNSCC.Molecules (Basel, Switzerland) · 2026Review
- CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting.Cancers · 2026Review
- Design of Experiments in the Formulation and Characterization of 3D-Printed Vaginal Films Loaded with Curcumin Solid Lipid Nanoparticles for Cervical Dysplasia.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Review
- Tumor immune microenvironment in non-small cell lung cancer progression.Frontiers in immunology · 2026Review
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
- T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction.Brain communications · 2026Review
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
- Metabolic licensing and restriction of innate immunity in the tumor microenvironment.Frontiers in immunology · 2026Review
- Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting.Frontiers in immunology · 2026Review
- RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Dendritic cells (DCs), as pivotal antigen-presenting cells (APCs), play crucial roles in initiating T cell-mediated antitumor immune responses, bridging innate and adaptive immunity while maintaining immune tolerance. With an in-depth understanding of DC biology and functions, numerous DC-targeted therapeutic approaches have been developed. An enhanced understanding of DC heterogeneity and DC cross-talk with other cells within the tumor microenvironment (TME), along with functional and metabolic remodeling mechanisms, may optimize DC-based cancer immunotherapies. This review focuses on the heterogeneity of the individual occurrence and function of DCs in tumors, elucidates the cross-talk between DCs and other cells in the TME, provides an in-depth understanding of the dysfunction and metabolic reprogramming of DCs in the TME, and summarizes existing DC-based anticancer therapies and novel therapeutic strategies, with the aim of providing new insight into the emerging role of DCs in future cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.